Morgan Stanley Pharma Cyte Biotech, Inc. Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
A detailed history of Morgan Stanley transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3 shares of PMCB stock, worth $6. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3
Previous 4
25.0%
Holding current value
$6
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PMCB
# of Institutions
33Shares Held
1.07MCall Options Held
5.4KPut Options Held
400-
K2 Principal Fund, L.P. Toronto, A6328KShares$655,0060.27% of portfolio
-
Geode Capital Management, LLC Boston, MA200KShares$400,5620.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA175KShares$349,2040.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$184,1747.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$165,4540.18% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $41.5M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...